This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: British Society of Heart Failure

January 2018 Online First

News from the British Society for Heart Failure 2017

Dr Simon Beggs

Abstract

30 years of heart failure Professor Theresa McDonagh (King’s College Hospital, London) opened this session with a ‘tour de force’ exposition on the development of clinical biomarkers in heart failure from bench to bedside, focussing specifically on the natriuretic peptide family. This remarkable story began with the discovery of atrial natriuretic peptide (ANP) in 1981, which was determined to be natriuretic after observation of its diuretic effect following experimental injection into rodents. Brain natriuretic peptide (BNP) was subsequently discovered in porcine cerebrum and thereafter found to predominantly derive from myocardium in

| Full text
A walk around the right heart

April 2014 Br J Cardiol 2014;21:(2) Online First

A walk around the right heart

Dr Lindsey Tilling

Abstract

The right ventricle ‘A walk around the heart’ was the title of the recent British Society of Heart Failure (BSH) day for training and revalidation. After passing through the left atrium and ventricle on our walk, we stopped at the right ventricle (RV). Our tour guide at this juncture was Professor Andrew Clark (Chair of Academic Cardiology, Hull York Medical School, and BSH President). The causes of RV dysfunction were outlined initially. These can broadly be divided into left heart disease (ischaemia, cardiomyopathy, valve disease), RV failure (as for left heart), pulmonary hypertension (pulmonary artery hypertension [PAH], thromboemboli

| Full text
News from the BSH 15th Annual Autumn Meeting

February 2013 Br J Cardiol 2013;20:18-9

News from the BSH 15th Annual Autumn Meeting

Abstract

Mineralocorticoid receptor antagonists Professor Faiez Zannad (Université de Lorraine, Nancy, France), the first of two guest lecturers, who has been an investigator in three major randomised controlled trials (RCT) of mineralocorticoid receptor antagonists (MRA) in heart failure,1-3 opened the first session. There was a particular focus on the recent EMPHASIS-HF trial,3 which recruited heart failure (HF) patients with left ventricular systolic dysfunction (ejection fraction [EF] ≤30%, or EF 30-35% with QRS duration >130 ms) and mild symptoms (New York Heart Association [NYHA] class II). Eplerenone treatment resulted in a 37% relative

| Full text
Heart failure: what’s new? The 2011 BSH medical training meeting

June 2011 Br J Cardiol 2011;18:113–14

Heart failure: what’s new? The 2011 BSH medical training meeting

Abstract

Neurohormonal blockade A cardiac resynchronisation therapy pacemaker (CRT-P), provides cardiac resynchronisation therapy and diagnostics to assist in patient management The meeting set off to a stimulating start with Professor Theresa McDonagh (Kings College Hospital, Chair of the British Society of Heart Failure) reviewing primarily the growing evidence for aldosterone antagonists in the management of systolic heart failure (HF). Large clinical trials have established the role of aldosterone antagonists, such as spironolactone, in severe systolic HF (Randomised Aldactone Evaluation Study – RALES) and eplerenone in acute myocardial infarcti

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now